Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Expenses (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Accumulated Expenses for 6 consecutive years, with $21075.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 6.1% year-over-year to $21075.0, compared with a TTM value of $21075.0 through Dec 2025, down 6.1%, and an annual FY2025 reading of $21075.0, down 6.1% over the prior year.
  • Accumulated Expenses was $21075.0 for Q4 2025 at SAB Biotherapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.0 million in Q1 2025 and bottomed at $21075.0 in Q4 2025.
  • Average Accumulated Expenses over 5 years is $1.0 million, with a median of $413601.0 recorded in 2022.
  • The sharpest move saw Accumulated Expenses plummeted 99.34% in 2024, then skyrocketed 16588.91% in 2025.
  • Year by year, Accumulated Expenses stood at $674858.0 in 2021, then fell by 24.15% to $511849.0 in 2022, then surged by 564.32% to $3.4 million in 2023, then tumbled by 99.34% to $22443.0 in 2024, then decreased by 6.1% to $21075.0 in 2025.
  • Business Quant data shows Accumulated Expenses for SABS at $21075.0 in Q4 2025, $3.7 million in Q3 2025, and $21542.0 in Q2 2025.